No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 6.5x · 10Y median 5.8x · 77th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 8
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:35:55.588Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Carlsmed, Inc. (CARL) stock was $15.02 as of Oct 6, 2026, 10:34 AM EDT, down 1.83% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +17.9%
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
Medical - Healthcare Information Services · Carlsbad, CA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.42
Revenue Est.
$19.17M
Last Quarter Results
EPS
$-0.39
vs Estimate
$-0.40
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CARL | $408.33M | $15.02 | -1.83% | +17.87% | N/A | N/A | N/A |
| 2SI | $408.23M | $19.68 | +0.43% | +60.42% | N/A | N/A | vs CARL |
| 3MYGN | $408.49M | $4.33 | -5.57% | -43.02% | -32.02% | -14.20% | vs CARL |
| 4AVIR | $405.75M | $5.07 | -1.17% | +76.42% | -34.44% | N/A | vs CARL |
| 5NGNE | $404.38M | $25.59 | -3.32% | +18.39% | -27.73% | -21.02% | vs CARL |
| 6EIKN | $412.54M | $7.62 | +1.06% | N/A | N/A | N/A | vs CARL |
forward FY estimate
N/A
$18.94M
vs Estimate
$17.99M
Consensus Rating
Based on 5 analysts
Average Price Target
$19.20
+27.8% upside
Low
$17.00
Current
$15.02
High
$23.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.38 | $-0.38 | $-0.38 | 2 |
| Quarter ending Dec 2026 | $-0.38 | $-0.37 | $-0.36 | 1 |
| Quarter ending Mar 2027 | $-0.35 | $-0.34 | $-0.33 | 1 |
| Quarter ending Jun 2027 | $-0.40 | $-0.39 | $-0.38 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.50 | $-1.45 | $-1.41 | 3 |
| FY 2027 | $-1.46 | $-1.40 | $-1.34 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $18.74M | $19.17M | $19.56M | 3 |
| Quarter ending Dec 2026 | $21.97M | $22.48M | $22.94M | 3 |
| Quarter ending Mar 2027 | $23.33M | $23.86M | $24.35M | 1 |
| Quarter ending Jun 2027 | $25.78M | $26.37M | $26.92M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $74.47M | $76.74M | $79.80M | 3 |
| FY 2027 | $104.94M | $108.13M | $112.44M | 3 |
